IO Biotech ApS is a clinical stage biotech company developing immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
IO Biotech has already shown clinical validation of an IDO vaccine in a clinical phase I trial in a small number of patients with non-small cell lung cancer (NSCLC). Vaccine-treated patients had significantly increased overall survival compared to non-vaccine-treated patients, and tumor regression was observed in one patient with liver metastasis.